Objective To analyze the incidence and cause of complications during and after interventional therapy for congenital heart disease (CHD). Methods From April 1986 to April 2009, 388 out of 6029 patients with CHD developed complications during and post interventional therapy, another 5 patients died post procedure, clinical data from these 393 patients were retrospectively analyzed. The patients with severe functional insufficiency requiring intervention or surgery during and after interventional therapy were classified as severe complications. Results The overall complication rate was 6. 44% [7.69% post atrial septal defect occlusion, 4.20% post patent ductus arteriosus (PDA) occlusion, 1.31% post percutaneous balloon pulmonary valvuloplasty, 14.94% post veatricular septal defect occlusion, 3.13% post percutaneous closure of aortopulmonary collaterals, 30.95% post catheter embolotherapy of pulmonary arteriovenous malformations, 12.50% post transcatheter closure of coronary artery fistulae, 20.00% post transcatheter closure of ruptured sinus of Valsava aneurysm, 66. 67% post percutaneous balloon aortic valvuloplasty]. The severe complication rate was 0.65% (39/6029). The procedure-related mortality rate was 0.08% (5/6029), 0.26% (2/761) post percutaneous balloon pulmonary valvuloplasty, 0.05% (1/2070)post PDA occlusion, 9.10% (1/11) post balloon atrial septostomy, 33.33% (1/3) post percutaneous balloon aortic valvuloplasty. Emergency Cardiovascular surgery rate was 0.22% (13/6029). Selective surgery was required in 0.13% (8/6029)of patients post procedure. Two patients (0.03%) received permanent pacemaker implantation. Conclusions The severe complications and mortality rate of interventional therapy for CHD are relative low. Post procedure follow-up is needed fro monitoring possible procedure-related complications.

Objective To investigate the occurrence rates and changing role of plasma antibodies to Aβs in normal aging and their enlightenment to the pathogenesis of Alzheimer's disease.Methods Paraffin serial sections from Tg2576 mouse brains were immunostained with 205 plasma samples from healthy cases aged from 1 to 91 years old to make a specific tissue amyloid plaque immunoreactivity analysis, and subsequently, immunoprecipitation of plasma with synthetic Aβ peptides and formic acid soluble amyloid Aβ fractions (FAβ) was employed to clarify the immunospecialties of autoantibodies to Aβs. Results Plasma autoantibodies to Aβs were found to be naturally present in all age periods, even in childhood and juvenile, the total occurrence rate was 35.6%, and they showed a special age-related U-typed trend during aging. Conclusions Plasma autoantibodies to Aβ can occur before amyloid plaques in brains, and with no relationship with brain Aβ burden.